We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Moderna previously received fast-track designations for three of its messenger RNA vaccine programs, including its investigational Zika vaccine. Read More
The FDA has granted Moderna’s COVID-19 vaccine candidate a fast-track designation, making it the first potential vaccine to receive the agency’s expedited review status. Read More
The EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended eight new drugs for approval at its April meeting, including copycat versions of Novo Nordisk’s NovoLog insulin and Novartis’ multiple sclerosis drug Gilenya. Read More